Invasive Fungal Infections Market to Reach $9.08 Billion by 2028, Fueled by Advancements in Diagnostic Technologies

The invasive fungal infections market size has grown strongly in recent years. It will grow from $7.21 billion in 2023 to $7.58 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to global spread of infections, hematopoietic stem cell transplants, aging population, hospital-acquired infections, environmental factors.

The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.08 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to global health preparedness, public health education, novel antifungal agents, climate change impact, multidisciplinary approaches. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, collaborations for drug development.

Market Overview -
Invasive fungal infections refer to severe diseases caused by pathogenic fungi that penetrate and spread within the body beyond the point of initial infection. These infections are characterized by the penetration of fungal organisms into deeper layers of tissue, such as the bloodstream, organs, or other body structures. Invasive fungal infection treatment typically includes using antifungal medications and surgical procedures to excise infected tissue in certain instances.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp

Impact Of Hiv Epidemic On The Invasive Fungal Infection Market
The rise in the population suffering from human immunodeficiency virus (HIV) is expected to propel the growth of the invasive fungal infection market going forward. HIV (Human Immunodeficiency Virus) infection is a virus that compromises the immune system's ability to defend against diseases and illnesses. The rising number of individuals with compromised immune systems, such as HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), increases the susceptibility to invasive fungal infections, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. For instance, in July 2023, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based United Nations program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Furthermore, there were approximately 1.3 million new HIV infections reported in 2022. Therefore, the rise in the population suffering from the human immunodeficiency virus (HIV) will drive the growth of the invasive fungal infection market.

Competitive Landscape -
Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

Advancements In Antifungal Drug Development And Market Competitiveness
Major companies operating in the invasive fungal infection market are focused on developing an antifungal drug such as Posaconazole to address the increasing demand for more effective and innovative treatments for fungal infections and gain a competitive edge in the market. Antifungal drugs such as Posaconazole are medications designed to treat fungal infections by inhibiting growth or killing the fungi responsible for the disease. For instance, in June 2021, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Posaconazol, a new triazole antifungal drug. It is effective against various invasive fungal diseases and is recommended as a second-line treatment for mucormycosis (black fungus). This drug is approved to prevent aspergillus and candida infections in immunocompromised patients and treat oropharyngeal candidiasis (OPC).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Key Segments -
The invasive fungal infections market covered in this report is segmented -
1) By Disease Type: Candidaemi And Invasive Candiasis, Intra Abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.